ACS sneakers programs to spotlight health and diet in cancer prevention
The inaugural 'Coaches vs. Cancer Suits and Sneakers' awareness weekend is set for January 29 through January 31, 2010. This event is a collaboration between the American Cancer Society (ACS) and the National Association of Basketball Coaches (NABC); over the last weekend in January, participating NABC coaches will be leaving their dress shoes at home and instead wearing sneakers along with their suits to games in support of the ACS. Fans attending games are encouraged to do the same.
The ACS is also launching the first 'Suits and Sneakers Challenge' and 'Wear Your Sneakers to Work Day', in which employees of participating companies make an ACS donation of at least $5 and earn the ability to wear sneakers to work.
The wider point here is to spotlight the positive role that exercise and diet play in reducing one's risk for developing cancer. To learn more about these initiatives, check out Coachesvscancer.org or the associated ASC press release.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
